Skip to main content
Fig. 3 | Journal of Biomedical Science

Fig. 3

From: A novel pseudovirus‐based mouse model of SARS-CoV-2 infection to test COVID-19 interventions

Fig. 3

Proof-of-principle reduction of SARS-CoV-2 PsV infection in vivo following RBD protein administration. Schedule of infection and RBD blocking (a). BALB/c mice were infected with AdV-hACE2 intranasally. Five days later, mice were treated with 30ug of RBD i.n. one hour before 19del or 19del + D614G pseudovirus infection. On Day 4 post-infection, mice were imaged for bioluminescence activity. Representative bioluminescence images of mice infected with 19del or 19del + D614G pseudovirus with or without RBD blocking (b). Quantification of bioluminescence signal of mice infected with 19del (c) or 19del + D614G (d) pseudovirus with or without RBD blocking showing significantly lower infection in mice treated with RBD protein compared to unblocked control. Data expressed as mean ± SEM. Student’s t test used to analyze differences between groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page